Pharma News

Lotus Pharmaceuticals, Teraju Pharma to market products

Lotus Pharmaceuticals and Teraju Pharma have entered a strategic partnership to market Lotus’s products in a range of therapeutic areas in Malaysia.

Teraju Pharma will be responsible for marketing and promoting the products using its relationships and infrastructure.

The company is a specialised pharmaceutical wholesaler and holds a licence, issued by the country’s ministry of health, to import non-registered pharmaceutical products, orphan drugs and other life-saving medicines.

It sources a wide range of branded or generic equivalent drugs from across the globe to meet the needs of the local market.

Lotus Pharmaceuticals CEO Petar Vazharov stated: “We are delighted at our new collaboration with Teraju.

“This partnership will enable us to establish a substantial presence in Malaysia, particularly in the oncology sector, which leverages high-quality manufacturing and a rich pipeline of products.”

The company confirmed that the alliance is in line with its strategic plan to expand in Southeast Asia.

The collaboration will launch a portfolio of products in the therapeutic categories of ophthalmology, cardio-metabolic and oncology, commencing in the fourth quarter of 2023.

Lotus Pharmaceuticals, Alvogen and NRx Pharmaceuticals recently signed a global collaboration agreement for the development and commercialisation of NRX-101 to treat suicidal treatment-resistant bipolar depression (S-TRBD). 

The company will buy worldwide rights for the therapy and handle its commercialisation activities in markets outside the US.



Source link
#Lotus #Pharmaceuticals #Teraju #Pharma #market #products

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *